Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: March 13, 2026
Company: Bone Biologics Corporation
Reporting Period: Current event reported on March 13, 2026.
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Burlington, MA. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, margin, or debt data. The filing text does not provide a clear value for these metrics.
Material Changes and Events
- At-The-Market (ATM) Offering: The Company filed a prospectus supplement to sell up to $1,064,000 worth of common stock under its existing "at the market" offering program.
- Sales Agent: H.C. Wainwright & Co., LLC will act as the sales agent pursuant to the Sales Agreement dated September 27, 2024.
- Registration Basis: The offering is conducted under a shelf registration statement on Form S-3 (File No. 333-288290), declared effective on September 2, 2025.
- Historical Context: The Company previously sold approximately $1.7 million of shares under a prior registration statement (File No. 333-265872), which is no longer effective.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the availability of shares for sale through the ATM program but provides no specific guidance on future sales timing, volume, or use of proceeds beyond the program limits.
Risks and Contingencies: The filing includes a standard disclaimer that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration or qualification. No other specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the current market price of BBLG to estimate the number of shares potentially issuable under the $1,064,000 limit.
- Review the full Prospectus Supplement and Base Prospectus (dated September 2, 2025) for detailed terms of the Sales Agreement.
- Monitor subsequent filings to determine the actual volume of shares sold and the timing of sales under this program.
- Check the Company's most recent 10-K or 10-Q for updated liquidity, cash position, and burn rate, as this 8-K does not contain financial performance data.